[1] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells, 2020,9(4):875.
[2] Aydin MM, Akcali KC. Liver fibrosis. Turk J Gastroenterol, 2018,29(1):14-21.
[3] Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med, 2019,65:37-55.
[4] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol,2019,70(1):151-171.
[5] Wake K. "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat,1971,132(4):429-462.
[6] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol,2017,14(7):397-411.
[7] Cai X, Wang J, Wang J, et al.Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy.Pharmacol Res,2020,155:104720.
[8] Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, et al. Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med, 2021,25(2):639-651.
[9] Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the drosophila toll protein signals activation of adaptive immunity. Nature,1997,388(6640):394-397.
[10] Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol, 2015,30(7):1190-1196.
[11] Garcia MM, Goicoechea C, Molina-A′lvarez M, et al. Toll-like receptor 4: A promising crossroads in the diagnosis and treatment of several pathologies. Eur J Pharmacol, 2020,874:172975.
[12] Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci, 2021,78(4):1233-1261.
[13] Hsieh WT, Hsu MH, Lin WJ, et al. Ergosta-7, 9 (11), 22-trien-3β-ol Interferes with LPS docking to LBP, CD14, and TLR4/MD-2 Co-receptors to attenuate the NF-κB inflammatory pathway in vitro and drosophila. Int J Mol Sci, 2021,22(12):6511.
[14] 鲍璐璐,崔立红. TLR4/MyD88/NF-κB信号通路的研究进展. 胃肠病学和肝病学杂志,2019,28(5):568-572.
[15] Shim DW, Heo KH, Kim YK, et al. Anti-inflammatory action of an antimicrobial model peptide that suppresses the TRIF-dependent signaling pathway via inhibition of Toll-like receptor 4 endocytosis in lipopolysaccharide-stimulated macrophages. PLoS One, 2015,10(5):e0126871.
[16] Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol, 2016,8(32):1354-1369.
[17] Liu L, Zhou Y, Dai D, et al. Antifibrotic effects of kangxian ruangan capsule on rats with nonalcoholic fatty liver fibrosis and hepatic stellate cells through regulation of TGF-β and TLR4 signaling pathways. Evid Based Complement Alternat Med, 2021,2021:5649575.
[18] Liu YF, Niu GC, Li CY, et al. Mechanism of ulcerative colitis-aggravated liver fibrosis: the activation of hepatic stellate cells and TLR4 signaling through gut-liver axis. Front Physiol, 2021,12:695019.
[19] Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 1999,11(1):115-122.
[20] 杜成成,尹婷,任如静,等. 基于脂多糖-Toll样受体4信号通路抗内毒素血症机制研究进展. 国际药学研究杂志,2017,44(12):1107-1112.
[21] Wang C, Ma C, Gong L, et al. Macrophage polarization and its role in liver disease. Front Immunol, 2021,12:803037..
[22] Gajalakshmi P, Majumder S, Viebahn CS, et al. Interleukin-6 secreted by bipotential murine oval liver stem cells induces apoptosis of activated hepatic stellate cells by activating NF-κB-inducible nitric oxide synthase signaling. Biochem Cell Biol, 2017,95(2):263-272.
[23] Wang A, Zhang F, Xu H, et al. TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways. Mol Immunol, 2017,87:67-75.
[24] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci, 2019,76(1):99-128.
[25] Kang HH, Kim IK, Lee HI, et al. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. Biochem Biophys Res Commun, 2017,490(2):349-355.
[26] Xu X, Wang W, Lin L, et al. Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats. Tissue Cell, 2020,66:101382.
[27] Parada E, Casas AI, Palomino-Antolin A, et al. Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models. Br J Pharmacol, 2019,176(15):2764-2779.
[28] Fort MM, Mozaffarian A, Stöver AG, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol, 2005,174(10):6416-6423.
[29] Ii M, Matsunaga N, Hazeki K, et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol, 2006,69(4):1288-1295. |
